Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma.

ABSTRACT:

Objective

Investigate the association between use of depot medroxyprogesterone acetate (DMPA) (an injectable progestin-only contraceptive) and leiomyoma development.

Methods

We conducted a cohort study in the Detroit, Michigan, area that involved four clinic visits at 20-month intervals over 5 years (2010-2018) and used a standardized ultrasonography protocol to prospectively measure leiomyomas 0.5 cm or more in diameter. Participants were 1,693 self-identified Black women aged 23-35 years with no prior leiomyoma diagnosis and no hysterectomy. For this substudy, years since last use of DMPA was ascertained from questionnaire data at every visit. Leiomyoma incidence was defined as the first visit with an observed leiomyoma among women who were leiomyoma-free at enrollment. De

SUBMITTER: Harmon QE 

PROVIDER: S-EPMC9015023 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature